Q-omics provides the consensus-scored IL20 profile across patient tissues and cancer cell-line models. IL20 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL20 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IL20 RNA expression shows 9,384 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, KIRC, and ESCA as cancer lineages where IL20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL20 survival associations across molecular data types. IL20 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL20 RNA expression–survival associations across cancer types. High IL20 expression shows unfavorable associations in KIRP, HNSC, CHOL and SCLC, but favorable associations in MESO and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL20 RNA expression.
This table summarizes IL20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IL20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL20 shows lower tumor expression in KIRC, UCEC, KIRP and LUAD and higher tumor expression in COAD and BRCA. The KIRC box plot shows higher IL20 RNA expression in normal versus tumor tissue (log2 FC = −0.168, t-test p < 0.001).
This table shows molecular features associated with IL20 in patient tissues and cancer cell lines. In patient samples, IL20 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IL20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
